Natera (NASDAQ:NTRA) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Monday.
NTRA has been the subject of a number of other reports. Craig Hallum began coverage on shares of Natera in a research report on Monday, April 9th. They set a “buy” rating and a $16.00 price target for the company. Zacks Investment Research cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. BidaskClub upgraded shares of Natera from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 20th. Finally, Morgan Stanley lifted their price target on shares of Natera from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.80.
Get Natera alerts:
Natera traded down $0.25, reaching $11.47, during trading on Monday, MarketBeat Ratings reports. 244,198 shares of the stock were exchanged, compared to its average volume of 137,967. The company has a debt-to-equity ratio of -18.90, a current ratio of 1.80 and a quick ratio of 1.68. Natera has a 1 year low of $11.42 and a 1 year high of $11.95. The company has a market capitalization of $638.89 million, a PE ratio of -4.78 and a beta of 2.07.
Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, May 8th. The medical research company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Natera had a negative return on equity of 752.93% and a negative net margin of 58.84%. The firm had revenue of $62.34 million for the quarter, compared to analysts’ expectations of $54.86 million. During the same period last year, the firm earned ($0.70) earnings per share. Natera’s revenue for the quarter was up 26.2% on a year-over-year basis. sell-side analysts forecast that Natera will post -2.05 EPS for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Trexquant Investment LP acquired a new stake in shares of Natera during the first quarter valued at about $119,000. MetLife Investment Advisors LLC acquired a new stake in shares of Natera during the fourth quarter valued at about $124,000. Jefferies Group LLC acquired a new position in shares of Natera in the fourth quarter valued at approximately $130,000. Wells Fargo & Company MN grew its holdings in shares of Natera by 69.2% in the third quarter. Wells Fargo & Company MN now owns 30,504 shares of the medical research company’s stock valued at $393,000 after purchasing an additional 12,473 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Natera by 13.2% in the first quarter. Swiss National Bank now owns 47,900 shares of the medical research company’s stock valued at $444,000 after purchasing an additional 5,600 shares in the last quarter. Institutional investors and hedge funds own 68.51% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
To view ValuEngine’s full report, visit ValuEngine’s official website.